ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Rodney Cheng-En Hsieh,Sunil Krishnan,Ren-Chin Wu,Akash R Boda,Arthur Liu,Michelle Winkler,Wen-Hao Hsu,Steven Hsesheng Lin,Mien-Chie Hung,Li-Chuan Chan,Krithikaa Rajkumar Bhanu,Anupallavi Srinivasamani,Ricardo Alexandre De Azevedo,Yung-Chih Chou,Ronald A DePinho,Matthew Gubin,Eduardo Vilar,Chao Hsien Chen,Ravaen Slay,Priyamvada Jayaprakash,Shweta Mahendra Hegde,Genevieve Hartley,Spencer T Lea,Rishika Prasad,Brittany Morrow,Coline Agnes Couillault,Madeline Steiner,Chun-Chieh Wang,Bhanu Prasad Venkatesulu,Cullen Taniguchi,Yon Son Betty Kim,Junjie Chen,Nils-Petter Rudqvist,Michael A Curran
DOI: https://doi.org/10.1126/sciimmunol.abl9330
2022-06-10
Abstract:Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)-expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirradiation CD47 levels. The combination of RT, anti-SIRPα, and anti-PD-1 reversed adaptive immune resistance and drove efficient TAA cross-presentation, resulting in robust TAA-specific CD8 T cell priming, functional activation of T effectors, and increased T cell clonality and clonal diversity. We observed significantly higher complete response rates to RT/anti-SIRPα/anti-PD-1 in both irradiated and abscopal tumors and prolonged survival in three distinct murine CRC models, including a cecal orthotopic model. The efficacy of triple combination therapy was STING dependent as knockout animals lost most benefit of adding anti-SIRPα and anti-PD-1 to RT. Despite activation across the myeloid stroma, the enhanced dendritic cell function accounts for most improvements in CD8 T cell priming. These data suggest ATR-mediated CD47 and PD-L1 up-regulation as a key mechanism restraining radiation-induced immune priming. RT combined with SIRPα and PD-1 blockade promotes robust antitumor immune priming, leading to systemic tumor regressions.